Liquid Biopsies, What We Do Not Know (Yet)

Alberto Bardelli, Klaus Pantel

Research output: Contribution to journalReview articlepeer-review


The inherent molecular heterogeneity of metastatic tumors and the ability of cancer genomes to dynamically evolve are not properly captured by tissue specimens. Analysis of cell-free DNA and circulating tumor cells has the potential to change clinical practice by exploiting blood rather than tissue as a source of information. Liquid biopsies are already used to monitor disease response and track the emergence of drug resistance. The suitability of blood-based molecular profiles for early detection and monitoring minimal residual disease is being evaluated. In this review, we address open questions in this fast-evolving field of research.

Original languageEnglish
Pages (from-to)172-179
Number of pages8
JournalCancer Cell
Issue number2
Publication statusPublished - Feb 13 2017

ASJC Scopus subject areas

  • Oncology
  • Cell Biology
  • Cancer Research


Dive into the research topics of 'Liquid Biopsies, What We Do Not Know (Yet)'. Together they form a unique fingerprint.

Cite this